












doi:10.101Comparison of Cytogenetic Clonal Evolution Patterns
following Allogeneic Hematopoietic Transplantation
versus Conventional Treatment in Patients
at Relapse of AML
Ulrike Bacher,1 Torsten Haferlach,2 Tamara Alpermann,2 Melanie Zenger,2 Nicolaus Kro¨ger,1
Dietrich W. Beelen,3 Wolfgang Kern,2 Susanne Schnittger,2 Claudia Haferlach2Relapse of acute myelogenous leukemia has been associated with clonal cytogenetic evolution, but no study
focused specifically on relapse after allogeneic hematopoietic stem cell transplantation (HSCT). We com-
pared karyotypes in 160 patients at both diagnosis and relapse either after allo-HSCT (n 5 26) or standard
chemotherapy (n5 134) using chromosome banding analysis combined with fluorescein in situ hybridization.
There were 71 females and 89 males (19.7-80.6 years). At diagnosis, aberrant karyotypes were more fre-
quent in the HSCT than in the chemotherapy cohort (16 of 26; 61.5% versus 63 of 134; 47.0%). This was
most obvious in patients with unfavorable cytogenetics (8 of 26; 30.8% versus 19 of 134; 14.2%; P 5 .032).
Differences in the karyotypes between diagnosis and relapse were more frequent in the allo-cohort
(14 of 26; 53.8% versus 49 of 134; 36.6%) than in the conventional cohort (n.s.), mainly because of newly
emerging cytogenetic alterations. Appearance of $3 new clonal alterations was more frequent in the allo-
cohort (6 of 12; 50.0%with clonal evolution versus 5 of 41; 12.2%, P5.005). Themean number of cytogenetic
alterations per patient was increasing from 2.0 at diagnosis to 4.0 at relapse in the allo-cohort, in the con-
ventionally treated patients from 0.9 to 1.3 (both P\ .001). Thus, higher frequencies of clonal evolution
and increasing cytogenetic complexity were observed in the stem cell recipients probably related to the
more unfavorable cytogenetic profiles already depicted at diagnosis.
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In acute myelogenous leukemia (AML), the stron-
gest antileukemic effect is provided by allogeneic
hematopoietic stem cell transplantation (HSCT).
However, considering the risks of allogeneic HSCT
and the heterogeneity of AML from clinical as well as
from genetic aspects [1,2], recent studies aim to select
patients with high-risk profiles for allogeneic HSCT,
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6/j.bbmt.2010.06.007standard chemotherapy [3-5]. The overrepresentation
of patients with adverse risk profiles in the transplant
setting is associated with high posttransplant relapse
rates between 30% and 50% depending on the
different subentities, the history of AML (de novo
versus secondary), or other parameters such as the
remission status before HSCT. Reduced-intensity
conditioning (RIC) regimens, which allowed the inclu-
sion of elderly patients or patients with comorbidities
[6], have less of an antileukemic effect and thus are
followed by higher relapse rates as well.
Relapse of AML has previously been associated
with cytogenetic clonal evolution in nearly 40% of pa-
tients when chromosome banding was performed [7].
Raghavan et al. [8] compared 27 paired diagnostic
and relapsedAMLsampleswith single nucleotide poly-
morphism (SNP) genotyping arrays. Newly acquired
segmental uniparental disomies (UPDs) were observed
at relapse in 11AMLsamples (40%), frequently includ-
ing 13q where the FLT3 gene is localized. Thus, acqui-
sition of a segmental UPD was shown to be a common
event associated with relapse of the AML. In acute1649
Table 1. Distribution of FAB Subtypes and Cytogenetic
Subgroups in the 26 AML Patients Who Relapsed after Allo-
geneic HSCT Cohort (allo-HSCT; n 5 26) versus 134 Patients
Who Relapsed after Conventional Treatment (Conv. Treat-







M0 1 (6.3%) 4 (4.0%)
M1 5 (31.3%) 15 (15.2%)
M2 3 (18.8%) 25 (25.3%)
M3/M3v — 3 (3.0%)
M4 4 (25.0%) 17 (17.2%)
M4eo — 7 (7.1%)
M5 — 10 (10.1%)
M6 2 (12.5%) 5 (5.1%)
M7 — 2 (2.0%)
s-AML following MDS 1 (6.3%) 11 (11.1%)
Total evaluable
(n 5 115)
16 (100.0%) 99 (100.0%)
Not evaluable 10 35
Cytogenetic prognostic
1650 Biol Blood Marrow Transplant 16:1649-1657, 2010U. Bacher et al.lymphoblastic leukemia (ALL), Kawamata et al. [9]
performed SNP-chip analysis in 14 pediatric patients
at diagnosis, remission, and relapse. With this highly
sensitive method, all 14 cases had genomic alterations
at relapse, and additional genomic abnormalities not
present at diagnosis were detected in 71% of cases.
On the other hand, they detected disappearance as
well of genomic alterations, especially deletions.
So far to our knowledge, only 1 study focused on
the cytogenetic evolution patterns in patients at relapse
of acute leukemias (AML and ALL) specifically after
allogeneic HSCT, but performed no direct compari-
son with the situation after conventional therapy
[10]. Here, we performed comparisons of the cytoge-
netic patterns in 160 patients at relapse and at diagnosis
of AML after allogeneic HSCT (n5 26) or after stan-
dard treatment (n 5 134) using chromosome banding
analysis and fluorescein in situ hybridization (FISH).groups (MRC criteria) [14]
Favorable risk — 17 (12.7%)
Intermediate risk 18 (69.2%) 98 (73.1%)
Poor risk 8 (30.8%) 19 (14.2%)
Total (n 5 160) 26 (100.0%) 134 (100.0%)
Cytogenetic subgroups
t(15;17) — 3 (2.2%)
t(8;21) — 7 (5.2%)
inv(16)/t(16;16) — 7 (5.2%)
Normal karyotype 10 (38.5%) 71 (53.0%)
+8 2 (7.7%) 6 (4.5%)
del(9q) 1 (3.8%) 2 (1.5%)
del(5q) 1 (3.8%) 3 (2.2%)
del(20q) — 1 (0.7%)
t(6;9) 1 (3.8%) 1 (0.7%)
t(3;21) — 1 (0.7%)
inv(3)/t(3;3) 3 (11.5%) —
Complex alterations 4 (15.4%) 9 (6.7%)
11q23/MLL — 8 (6.0%)
+4 — 3 (2.2%)
+11 — 2 (1.5%)
+21 1 (3.8%) 2 (1.5%)
Other trisomies — 1 (0.7%)
Other bal. rearrangements 2 (7.7%) 4 (3.0%)
Other alterations 1 (3.8%) 3 (2.2%)
Total (n 5 160) 26 (100.0%) 134 (100.0%)
MDS indicates myelodysplastic syndrome; AML, acute myelogenous leu-
kemia; HSCT, hematopoietic stem cell transplantation.PATIENTS AND METHODS
Patients
This retrospective analysis was based on a total of
160 patients (71 females, 89 males; median age, 62.6
years; range: 19.7-80.6 years) who developed relapse
of AML after allogeneic HSCT (n 5 26) or conven-
tional treatment (n 5 134). The basis for inclusion of
patients in the study was the availability of cytogenetic
results at both diagnosis and relapse, respectively, in-
vestigated in our laboratory. One hundred thirty-four
patients had de novo AML, 12 had secondary AML
after myelodysplastic syndrome (s-AML), and 13 had
therapy associated AML (t-AML) (history of AML
was missing in 1 case) (Table 1). In the HSCT cohort,
11 patients each had received myeloablative (MA) con-
ditioning and RIC, respectively (data on conditioning
regimens was not available in 4 stem cell recipients).
Bone marrow (BM) samples were sent between August
2005 and June 2009 fromdifferent hematologic centers
and clinics to the MLLMunich Leukemia Laboratory
for diagnostic workup. Patients agreed with the use of
laboratory data for research studies when they gave
written consent to the performance of genetic analysis
of BM samples. The study was performed in accor-
dance with the declaration of Helsinki.
Parameters Assessed
Cytomorphology
Morphologic classification of AML cases was
performed according to the FAB system [11,12].
Cytogenetics
Chromosome banding technique and FISH were
performed according to standard methods [13]. Fol-
lowing the WHO classification of 2008, cases werecategorized in the following cytogenetic subgroups:
t(15;17)(q22;q12), t(8;21)(q22;q22), inv(16)/t(16;16)
(p13;q22), normal karyotype, trisomy 8 (18) as sole
abnormality or in combination with other aberrations,
deletions of 5q, 9q, and 20q, t(6;9)(p23;q34), t(3;21)
(q26;q22), inv(3)/t(3;3)(q21;q26), complex aberrations
($3 clonal cytogenetic abnormalities), 11q23/MLL re-
arrangements, numeric gains of chromosomes 4, 11, or
21, other trisomies, other unbalanced and balanced
alterations, and alterations that did not correspond to
either of the mentioned groups (‘‘others’’). The prog-
nostic categorization of karyotypes was performed
according to revised MRC criteria [14]. Further, we
documented the numbers of cytogenetic alterations,
both at diagnosis and relapse of AML. The numbers
Biol Blood Marrow Transplant 16:1649-1657, 2010 1651Clonal Evolution in Stem Cell Recipients with AMLof numeric gains, losses, unbalanced structural, and
balanced rearrangements were recorded both at diag-
nosis and relapse. Only patients, in whom results of
chromosome banding analysis were available at diag-
nosis and at relapse from our our own laboratory,
were included in the study.
To analyze the presence of clonal evolution and to
characterize its patterns, we first documented differ-
ences in cytogenetics between diagnosis and relapse
in each patient. Second, patients with cytogenetic dif-
ferences were categorized whether they showed cyto-
genetic evolution (ie, acquisition of new cytogenetic
alterations), or clonal cytogenetic regression (ie, loss
of previously detectable cytogenetic alterations). The
combination of clonal evolution and clonal regression
was documented as well. The types of additional
cytogenetic changes were characterized as follows:
balanced rearrangements, unbalanced aberrations, or
complex alterations (when patients developed at least
3 new chromosomal alterations). The appearance of
a new independent clone was separately documented.
Statistics
For comparison of dichotomous variables between
the different groups, the 2-sided Fisher’s exact test was
used. Differences in the distributions of prognostic
factors in subgroups were analyzed by chi-square,
Fisher’s exact test, and by Wilcoxon test. Survival
was defined as the time from diagnosis to death or
date of the last follow-up. All tests were 2-sided, ac-
cepting P # .05 as indicating a statistically significant
difference. Statistical analysis was performed with the
SPSS software (version 14.0; SPSS, Chicago, IL).Table 2a. Differences of Cytogenetic Patterns from Di-
agnosis to Relapse of AML in the Recipients of Allogeneic
HSCT (allo-HSCT; n 5 26) and in the Conventionally Treated
Cohort (conv.; n5134)
Parameter Allo-HSCT Conv. Treatment
Clonal changes from diagnosis to
relapse
14/26 (53.8%) 49/134 (36.6%)
Clonal cytogenetic evolution at
relapse
12/26 (46.2%) 41/134 (30.6%)
Gain of balanced translocations* 5/12 (41.7%) 12/41 (29.3%)
Gain of unbalanced alterations* 1/12 (8.3%) 24/41 (58.5%)
Gain of complex alterations
($3 new alterations)*
6/12 (50.0%) 5/41 (12.2%)
New cytogenetically independent
clone*
2/12 (16.7%) 5/41 (12.2%)
Clonal regression 3/26 (11.5%) 17/134 (12.7%)
Clonal evolution and regression in
parallel
1/26 (3.8) 8/134 (6.0%)
HSCT indicates hematopoietic stem cell transplanatation; AML, acute
myelogenous leukemia.
*Only cytogenetically aberrant cases were included in the calculation.RESULTS
In the 26 stem cell recipients, recurrence of disease
was diagnosed with a median interval of 276 days post-
transplant (range: 71-683 days). In the conventionally
treated cohort consisting of 134 patients, 121 patients
were included in the study at first relapse with amedian
interval of 320 days (range: 73-1259 days from stan-
dard treatment from day 1), and 13 patients at the sec-
ond relapse with a median interval of 555 days from
diagnosis (range: 103-966 days) as cytogenetic results
were available from this time point only.
Cytomorphology and Cytogenetics at Diagnosis
of Disease
Table 1 shows the distribution of FAB subtypes,
the cytogenetic categories, and the subdivision of cyto-
genetic cases according to the different prognostic
subgroups following the revised MRC criteria [14].
Cytogenetic aberrations at diagnosis were more fre-
quent in the allogeneic HSCT group (16 of 26;
61.5%) than in the control cohort (63 of 134; 47.0%)(n.s.). In the cohort of the conventionally treated pa-
tients, a total of 17 of 134 (12.7%) had favorable karyo-
types in comparison to no patient in the cohort of the
allo-transplanted patients (n 5 0 of 26). Unfavorable
karyotypes were found in the HSCT cohort in 8 of
26 (30.8%) cases in comparison to 19 of 134 (14.2%)
in the standard chemotherapy group. Intermediate
karyotypes were identified in 18 of 26 (69.2%) of pa-
tients from the HSCT cohort versus 98 of 134
(73.1%) (Table 1).
Comparison of Cytogenetic Patterns at
Diagnosis and at Relapse
Aberrant karyotypes at diagnosis and relapse
First, we compared the frequencies of aberrant kar-
yotypes at diagnosis and relapse in both cohorts (Table
2A and Figure 1A). At diagnosis, aberrant karyotypes
were more frequent in the allogeneic HSCT group
(16 of 26; 61.5%) than in the conventionally treated
cohort (63 of 134; 47.0%; n.s.). At relapse, because of
cytogenetic clonal evolution, aberrant karyotypes
showed an increase in both cohorts but were still signif-
icantly more frequent in the HSCT cohort (20 of 26;
76.9%) than in the conventionally treated patients (73
of 134; 54.5%; P 5 .049). (Cytogenetic changes from
diagnosis to relapse are explained below inmore detail.)
At diagnosis there was a higher frequency of unfa-
vorable karyotypes in the HSCT cohort (8 of 26;
30.8%) in comparison with 19 of 134 (14.2%) in the
conventionally treated cohort (P 5 .032).
Clonal cytogenetic changes from diagnosis
to relapse
Differences in the cytogenetic patterns between
diagnosis and relapse weremore frequent in the alloge-
neic HSCT cohort (Figure 2A-D) than after standard
treatment (Table 2a, and Figures 1A and 3A-D): in
Figure 1. (A) Frequency of aberrant karyotypes (KTs) and of clonal evolution at diagnosis and at relapse of AML. The recipients of allogeneicHSCT (allo-
HSCT; n5 26) and patients with conventional treatment were compared (conv.; n5 134). The symbol * above the columns indicates that the frequency
showed statistically significant differences between diagnosis and relapse (see as well Table 2b). (B)Mean numbers of cytogenetic alterations per patient at
diagnosis and at relapse of AML in the recipients of allogeneic HSCT (allo-HSCT; n 5 26) and in the conventionally treated cohort (conv.; n 5 134).
1652 Biol Blood Marrow Transplant 16:1649-1657, 2010U. Bacher et al.the HSCT cohort, 14 of 26 (53.8%) were observed
with changes in karyotypes, but only 49 of 134
(36.6%) of the conventionally treated patients (n.s.).
The differences of clonal alterations in both cohorts
were mostly because of the appearance of new cytoge-
netic alterations at relapse (‘‘clonal cytogenetic
evolution’’). Again, acquisition of new cytogenetic alter-
ations was more frequently observed in the HSCT co-hort when compared to the conventionally treated
patients (12 of 26; 46.2%; versus 41 of 134; 30.6%).
These differences between both cohorts, however, did
not reach statistical significance, probably because of
the limited number of patients in the HSCT cohort.
Focusing on the HSCT cohort, cytogenetic chan-
ges at relapse were more frequent in the cohort of the
RIC patients (8 of 11; 72.7%) when compared to the
Figure 2. Illustration of the cytogenetic patterns with the support of CYDAS (http://www.cydas.org/OnlineAnalysis/) [21]. Chromosomal gains are
marked in green to the right, losses in red to the left. The thickness of the bars represents the number of cases showing the respective chromosomal
gain or loss. Figure 2A Illustrates the cytogenetic alterations in the cohort with allogeneic hematopoietic stem cell transplantation (HSCT) at diagnosis,
2B at relapse. Figures 2C and D demonstrate clonal evolution and regression patterns, respectively.
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sition of new cytogenetic changes was observed in 7 of
11 patients from the RIC cohort (63.6%), and in 4 of
11 MA conditioned patients (36.4%) (n.s.). (Data on
conditioning strategies were missing in 4 patients).
In addition, we performed univariate analysis, taking
age, interval of relapse from HSCT, history of AML
(de novo versus secondary), and the occurrence of
chromosomal changes at relapse on subsequent sur-
vival outcomes in the HSCT cohort into account.
We observed no significant influences of these param-
eters. This, however, might have been because of the
limited size of the HSCT cohort.
Loss of a cytogenetic clonal alteration (‘‘clonal
regression’’) was similarly distributed in both cohorts
(allogeneic HSCT: 3 of 26; 11.5%; conventional treat-
ment: 17 of 134; 12.7%). Clonal regression wasfrequently represented by loss of a trisomy 8 (HSCT
cohort: n 5 1; conventional cohort: n 5 5) (Figures
2D and 3D). One patient from the HSCT group
(3.8%) and 8 patients from the conventional cohort
(6.0%) showed appearance of new cytogenetic alter-
ations and loss of other alterations in parallel (n.s.).
Characterization of the new cytogenetic
alterations at relapse
The types of new genetic alterations differed be-
tween the allo-cohort and the conventionally treated
patients significantly (Table 2a): patients from the
HSCT cohort developed new complex aberrations—
being defined by the appearance of $3 clonal cytoge-
netic alterations—in 6 of those 12 cases (50.0%) with
the phenomenon of clonal cytogenetic evolution,
whereas in the conventionally treated cohort, complex
Figure 3. Figures 3A-D demonstrate the cytogenetic patterns in the conventionally treated cohort: 3A at diagnosis, 3B at relapse, 3C clonal evolution,
and 3D clonal regression.
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the new chromosomal alterations (P 5 .005). New in-
dependent clones were similar in both cohorts (HSCT
cohort: 2 of 12; 16.7%; conventional treatment: 5 of
41; 12.2%). Balanced translocations were observed in
5 of 12 patients from the HSCT cohort (41.7%) and
in 12 of 41 (29.3%) from the conventional cohort
(n.s.) (only cytogenetically aberrant patients being
considered for the calculation).
In the HSCT cohort, clonal evolution at relapse of
AMLwas frequently represented by structural losses of
5q or 9q, or structural gains of 15q. In the standard
treatment cohort, clonal evolution was most fre-
quently being represented by trisomy 8 or structural
gains of 11q or 17q (Figures 2C and 3C). Clonal
regression showed clustering with regard to trisomy
8 or structural losses of 11p in the standard treatment
cohort (in the HSCT cohort, only 3 patients showed
clonal regression at relapse) (Figures 2D and 3D).Finally, we analyzed the frequency of clonal cytoge-
netic evolution in the larger cytogenetic subgroups
(normal karyotype, 18, and complex aberrant karyo-
types) in the total cohort. In the patients with a normal
karyotype, 21 of 81 (25.9%) showed clonal cytogenetic
evolution. This was only slightly less frequent when
compared to the subgroups with trisomy 8 (3 of 8;
37.5%), or with complex aberrant karyotypes (5 of 13;
38.5%). When both cohorts were investigated sepa-
rately (allo-HSCT versus conventional treatment), 4
of 10 stem cell recipients (40.0%) with normal karyo-
types at the first manifestation of AML showed clonal
cytogenetic evolution at posttransplant relapse, which
was similar to the conventional cohort (17 of 71;
23.9%). No stem cell recipient with a 18 (n 5 2)
developed clonal evolution in comparison to 3 of 6
(50.0%) with conventional treatment. Patients with
complex aberrant karyotypes from the allo-HSCT
cohort were more frequently observed with clonal
Biol Blood Marrow Transplant 16:1649-1657, 2010 1655Clonal Evolution in Stem Cell Recipients with AMLevolution (3 of 4; 75.0%)when compared to the conven-
tionally treated cohort (2 of 9; 22.2%). However, the
limited size of the cytogenetic subgroups does not
allow any further conclusions.Complexity of cytogenetic patterns
Cytogenetic patterns were more complex in the al-
logeneic HSCT patients when compared to the stan-
dard cohort both at diagnosis and at relapse of AML
(Table 2b and Figure 1A).
At diagnosis of AML, the HSCT patients had
a mean number of 2.0 (standard deviation, SD; 63.0)
cytogenetic alterations, the conventionally treated
patients had a mean number of 0.9 6 1.5 (P 5 .005).
At relapse, those from the allogeneic HSCT cohort
were observed with a mean number of 4.0 6 5.4 cyto-
genetic alterations per patient in comparison to amean
of 1.3 6 2.0 cytogenetic alterations per patient in the
conventionally treated cohort (P \ .001). Thus, in
the HSCT cohort, the mean difference in the numbers
of cytogenetic alterations between diagnosis and re-
lapse per patient was 2.0, whereas in the conventional
cohort it was 0.4 (P\ .001).
In more detail, the mean numbers of numeric los-
ses per patient were significantly higher in the HSCT
patients when compared to the standard cohort at di-
agnosis (HSCT: 0.2 6 0.6; conventional: 0.1 6 0.2;
P 5 .020) as at relapse (HSCT: 0.3 6 0.7; conven-
tional: 0.1 6 0.3; P 5 .001). Also, HSCT patients
had significantly higher mean numbers of structural
unbalanced alterations at diagnosis and relapse of
AML than the standard cohort (diagnosis: HSCT:
mean number, 1.2 6 2.6; conventional: 0.4 6 1.2;
P 5 .014; relapse: HSCT: mean, 2.7 6 5.1; conven-
tional: mean: 0.6 6 1.5; P\ .001) (Figure 1B).
Regarding themean numbers of numeric gains and
balanced rearrangements, there was no significant
difference between the allo-HSCT cohort and the
conventionally treated patients at diagnosis and re-
lapse (mean number of numeric gains at diagnosis:
HSCT: 0.3 6 0.7; conventional: 0.2 6 0.6; relapse:
HSCT: 0.4 6 0.9; conventional: 0.3 6 0.7; balancedTable 2b. Characterization of Cytogenetic Alterations atDiagnosis
HSCT; n 5 26) and in the Conventionally Treated Cohort (Conv.; n
Diagnosis
Parameter Allo-HSCT Conv.
Patients with aberrant karyotypes 16/26 (61.5%) 63/134 (47.0%)
Mean no of alterations (±SD)
Total 2.0 (±3.0) 0.9 (±1.5)
Numerical gains 0.3 (±0.7) 0.2 (±0.6)
Numerical losses 0.2 (±0.6) 0.1 (±0.2)
Struct. unbal. alterations 1.2 (±2.6) 0.4 (±1.2)
Balanced rearrangements 0.3 (±0.4) 0.2 (±0.4)
SD indicates standard deviation; HSCT, hematopoietic stem cell transplanatatrearrangements at diagnosis: HSCT: 0.3 6 0.4; con-
ventional: 0.2 6 0.4; relapse: HSCT: 0.7 6 0.9; con-
ventional: 0.3 6 0.7).DISCUSSION
Because of the selection of poor risk AML cases for
allogeneic HSCT [3-5], relapse in the posttransplant
period remains a central problem in hematopoietic
stem cell transplantation. Several studies focused on
the early detection of relapse of AML in the
posttransplant period with assessment of minimal
residual disease or chimerism analysis [15,16], or on
therapeutic strategies in this difficult clinical situation
[17,18]. However, not much is known about the
specific biology of relapsed AML in the posttransplant
period in comparison to relapse after standard
chemotherapy of AML. Although previous studies
demonstrated that relapse of an acute leukemia was
frequently accompanied by the acquisition of new
cytogenetic alterations [8,9], to our knowledge, so far
no study performed comparison of cytogenetic clonal
evolution in recipients of allogeneic HSCT versus
conventional therapy in patients with AML. Recently,
Schmidt-Hieber et al. [10] analyzed the cytogenetic
patterns of 22 patients relapsing from AML and ALL
after allogeneicHSCTand described changes of karyo-
types in 68% of patients from this cohort.
In this study, we compared the patterns of clonal
cytogenetic evolution in 160 patients with relapse of
AML either after allogeneic HSCT or after conven-
tional chemotherapy. First, alterations of the cytoge-
netic patterns from the first manifestation of AML to
relapse were more frequently seen in the recipients of
HSCT with 53.8% of affected cases than in the con-
ventionally treated cohort with 36.6% of cases. These
different cytogenetic patterns were most frequently
because of the acquisition of new cytogenetic alter-
ations (‘‘clonal evolution’’) with a higher frequency in
the HSCT cohort when compared to the convention-
ally treated patients (46.2% veresus 30.6%). Loss of
clonal alterations at relapse—corresponding to clonalandRelapse of AML in theRecipients of AllogeneicHSCT (allo-
5 134)
Relapse
P Allo-HSCT Conv. P
n.s. 20/26 (76.9%) 73/134 (54.5%) .049
.005 4.0 (±5.4) 1.3 (±2.0) <.001
n.s. 0.4 (±0.9) 0.3 (±0.7) n.s.
.020 0.3 (±0.7) 0.1 (±0.3) .001
.014 2.7 (±5.1) 0.6 (±1.5) <.001
n.s. 0.7 (±0.9) 0.3 (±0.7) .067
ion; AML, acute myelogenous leukemia.
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conventional cohort: 12.7%). When the types of new
cytogenetic alterations were characterized in more de-
tail, some striking differences were observed between
the cohorts: the transplant patients showed a higher
frequency of new complex cytogenetic alterations,
meaning the acquisition of at least 3 new clonal cytoge-
netic alterations, when compared to the conventionally
treated cohort (50.0% versus 12.2% of those with the
phenomenon of clonal cytogenetic evolution).
We then compared the cytogenetic complexity of
the stem cell recipients and those from the convention-
ally treated cohort. Stem cell recipients had a signifi-
cantly higher mean number of cytogenetic alterations
at relapse of AML when compared to the convention-
ally treated cohort (4.0 versus 1.3 alterations per pa-
tient; P 5 .005) and the difference between the mean
number of cytogenetic alterations per patient from di-
agnosis to relapse was 2.0 in the HSCT cohort but 0.4
only in the standard-treated patients (P\ .001). Fur-
ther, the HSCT patients showed significantly higher
mean numbers of numeric losses and unbalanced
structural rearrangements at diagnosis as at relapse
when compared to the conventionally treated cohort.
Thus, higher rates of clonal evolution and higher
cytogenetic complexity at relapse and at diagnosis
were observed in the HSCT patients in our study.
These results suggest higher levels of genetic instability
at diagnosis, but also at relapse in the allo-transplant co-
hort, which might be seen in association to the more
adverse and complex cytogenetic profiles of patients
already at diagnosis of AML: according to the earlier
results, theHSCTpatients had higher rates of abnormal
karyotypes, a higher frequency of unfavorable karyo-
types (30.8% versus 14.2%), and higher complexity of
karyotypes already at diagnosis of AMLwhen compared
to the conventionally treated patients. Second, the
higher treatment intensity regarding conditioning regi-
mens in the HSCT patients when compared to those
with conventional treatment might play a role.
As data on AML is missing so far, we compared our
results to chronicmyelogenous leukemia: patients with
relapse or persistence of the disease after HSCT were
reported to show different cytogenetic patterns when
compared to those after autologous HSCT [19,20].
Karrman et al. [20] reviewed 131 patients with CML
with cytogenetic evolution after allogeneic or autolo-
gous HSCT. In the recipients of allogeneic HSCT,
major route abnormalities were underrepresented
with 15% of all cases only when compared to 67% in
autologous HSCT (P 5 .07), and balanced transloca-
tions were significantly more frequent (66 versus
22%, P 5 .03). There was a trend toward pseudodi-
ploidy after allogeneic HSCT in contrast to a trend
toward hyperdiploidy after autologousHSCT. Factors
such as BM environment, the presence of donor cells,
or immunosuppression were suggested to explain thedifferent cytogenetic evolution patterns in CML pa-
tients post allo-HSCT. Thus, it seems that in CML,
the differences of the cytogenetic evolution patterns
in dependence of the previous treatment strategies
might be more pronounced than in AML as we were
not able to determine such substantial differences in
the types of cytogenetic alterations.
In conclusion, patients who relapse from AML af-
ter allogeneic HSCT have a higher frequency of clonal
cytogenetic evolution and show higher genetic com-
plexity at relapse when compared to patients who re-
lapse after standard chemotherapy. These results
suggest higher genetic instability probably associated
to the more unfavorable cytogenetic profiles already
at diagnosis of AML when both cohorts are compared,
and themore advanced clinical stages of theHSCTpa-
tients have to be considered as well. Thus, the cytoge-
netic characterization of relapse of AML in stem cell
recipients helps to explain the adverse prognosis of
stem cell recipients at relapse of AML and emphasizes
the need for specific and novel treatment approaches
for this high risk cohort. Future studies should focus
on the clinical impact of cytogenetic patterns in pa-
tients with posttransplant relapse of AML. Finally,
the inclusion of larger cohorts of HSCT recipients
would allow the correlation of the individual stages of
AML before transplantation with the frequency and
the clonal evolution patterns at posttransplant relapse.ACKNOWLEDGMENTS
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